Ascendiant Capital Starts Echo Therapeutics (ECTE) at Buy
Tweet Send to a FriendGet Alerts ECTE Hot Sheet
Price: $0.58 +5.45%
Rating Summary:
8 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
8 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade ECTE Now!
Ascendiant Capital initiates coverage on Echo Therapeutics (NASDAQ: ECTE) with a Buy. PT $2.00.
The firm is calling ECTE, "an intriguing continuous glucose monitor play."
"We anticipate that Echo will commence a 50 patient pivotal study of the Symphony device around the end of this year, intended to obtain the CE Mark for the device by the end of 2013. We would then expect the Company to conduct a subsequent pivotal study in the U.S. designed to achieve FDA approval, which we estimate could be secured in 2015."
For an analyst ratings summary and ratings history on Echo Therapeutics click here. For more ratings news on Echo Therapeutics click here.
Shares of Echo Therapeutics closed at $1.47 yesterday, with a 52 week range of $1.38-$4.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm is calling ECTE, "an intriguing continuous glucose monitor play."
"We anticipate that Echo will commence a 50 patient pivotal study of the Symphony device around the end of this year, intended to obtain the CE Mark for the device by the end of 2013. We would then expect the Company to conduct a subsequent pivotal study in the U.S. designed to achieve FDA approval, which we estimate could be secured in 2015."
For an analyst ratings summary and ratings history on Echo Therapeutics click here. For more ratings news on Echo Therapeutics click here.
Shares of Echo Therapeutics closed at $1.47 yesterday, with a 52 week range of $1.38-$4.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Echo Therapeutics (ECTE) Gets IRB Approval for Symphony CGM System
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- Echo Therapeutics Announces Successful Unveiling of Symphony® CGM System
Create E-mail Alert Related Categories
New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
